Table of Contents
International Scholarly Research Notices
Volume 2014 (2014), Article ID 653045, 11 pages
http://dx.doi.org/10.1155/2014/653045
Review Article

C-Reactive Protein: An In-Depth Look into Structure, Function, and Regulation

1Endocrine and Metabolic Diseases Research Center, School of Medicine, Zulia University, 20th Avenue, Maracaibo 4004, Venezuela
2Institute of Clinical Immunology, University of Los Andes, Mérida 5101, Mérida, Venezuela

Received 31 August 2014; Accepted 1 November 2014; Published 16 December 2014

Academic Editor: Jose Antonio F. Ramires

Copyright © 2014 Juan Salazar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. World Health Organization, “Global status report on non-communicable disease,” 2010, http://www.who.int/nmh/publications/ncd_report2010/en.
  2. Ministerio del Poder Popular para la Salud de la República Bolivariana de Venezuela, Annuary of Mortality 2011, Ministerio del Poder Popular para la Salud de la República Bolivariana de Venezuela, Caracas, Venezuela, 2014, (Spanish), http://www.mpps.gob.ve/index.php?option=com_phocadownload&view=category&id=11:anuarios-de-mortalidad.
  3. Organización Panamericana de la Salud, “Información y Análisis de Salud: Situación de Salud en las Américas: Indicadores Básicos 2011,” Washington, DC, USA, 2009, http://www.paho.org/hq/dmdocuments/2009/IB_SPA_2009.pdf.
  4. E. Vartiainen, “Controlling the cardiovascular disease epidemic,” Journal of Internal Medicine, vol. 263, no. 6, pp. 623–625, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. Third Report of the National Cholesterol Education Program (NCEP), “Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults adult treatment panel III, Final Report,” Circulation, vol. 106, pp. 3143–3421, 2002. View at Google Scholar
  6. M. Miller, N. J. Stone, C. Ballantyne et al., “Triglycerides and cardiovascular disease: a scientific statement from the American heart association,” Circulation, vol. 123, pp. 2292–2333, 2011. View at Publisher · View at Google Scholar
  7. R. N. Rodionov and S. R. Lentz, “The homocysteine paradox,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 6, pp. 1031–1033, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Devaraj, S. Valleggi, D. Siegel, and I. Jialal, “Role of C-reactive protein in contributing to increased cardiovascular risk in metabolic syndrome,” Current Atherosclerosis Reports, vol. 12, no. 2, pp. 110–118, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Teupser, O. Weber, T. N. Rao, K. Sass, J. Thiery, and H. J. Fehling, “No reduction of atherosclerosis in C-reactive protein (CRP)-deficient mice,” The Journal of Biological Chemistry, vol. 286, no. 8, pp. 6272–6279, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Koike, S. Kitajima, Y. Yu et al., “Human C-reactive protein does not promote atherosclerosis in transgenic rabbits,” Circulation, vol. 120, no. 21, pp. 2088–2094, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. E. Grad and H. D. Danenberg, “C-reactive protein and atherothrombosis: cause or effect?” Blood Reviews, vol. 27, no. 1, pp. 23–29, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. P. M. Ridker, “C-Reactive protein: eighty years from discovery to emergence as a major risk marker for cardiovascular disease,” Clinical Chemistry, vol. 55, no. 2, pp. 209–215, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Dhingra, P. Gona, B.-H. Nam et al., “C-reactive protein, inflammatory conditions, and cardiovascular disease risk,” The American Journal of Medicine, vol. 120, no. 12, pp. 1054–1062, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Mantovani, C. Garlanda, A. Doni, and B. Bottazzi, “Pentraxins in innate immunity: From C-reactive protein to the long pentraxin PTX3,” Journal of Clinical Immunology, vol. 28, no. 1, pp. 1–13, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Thompson, M. B. Pepys, and S. P. Wood, “The physiological structure of human C-reactive protein and its complex with phosphocholine,” Structure, vol. 7, no. 2, pp. 169–177, 1999. View at Publisher · View at Google Scholar · View at Scopus
  16. F. Heres, A. Peix, R. Ravelo, and O. González, “Proteína C reactiva y enfermedad arterial coronaria,” Revista Cubana de Cardiología y Cirugía Cardiovascular, vol. 17, pp. 69–79, 2011. View at Google Scholar
  17. S. Black, I. Kushner, and D. Samols, “C-reactive protein,” The Journal of Biological Chemistry, vol. 279, no. 47, pp. 48487–48490, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Nanri, M. A. Moore, and S. Kono, “Impact of C-reactive protein on disease risk and its relation to dietary factors: literature review,” Asian Pacific Journal of Cancer Prevention, vol. 8, no. 2, pp. 167–177, 2007. View at Google Scholar · View at Scopus
  19. G. C. Brooks, M. J. Blaha, and R. S. Blumenthal, “Relation of C-reactive protein to abdominal adiposity,” The American Journal of Cardiology, vol. 106, no. 1, pp. 56–61, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Scotece, J. Conde, R. Gómez et al., “Role of adipokines in atherosclerosis: interferences with cardiovascular complications in rheumatic diseases,” Mediators of Inflammation, vol. 2012, Article ID 125458, 14 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. M. J. Puglisi and M. L. Fernandez, “Modulation of C-reactive protein, tumor necrosis factor-α, and adiponectin by diet, exercise, and weight loss,” Journal of Nutrition, vol. 138, no. 12, pp. 2293–2296, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Singh, M. Hoffmann, R. Wolk, A. S. M. Shamsuzzaman, and V. K. Somers, “Leptin induces C-reactive protein expression in vascular endothelial cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 9, pp. e302–e307, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Kwon and J. E. Pessin, “Adipokines mediate inflammation and insulin resistance,” Frontiers in Endocrinology, vol. 4, Article ID Article 71, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. N. Ouchi, J. L. Parker, J. J. Lugus, and K. Walsh, “Adipokines in inflammation and metabolic disease,” Nature Reviews Immunology, vol. 11, no. 2, pp. 85–97, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Taube, R. Schlich, H. Sell, K. Eckardt, and J. Eckel, “Inflammation and metabolic dysfunction: links to cardiovascular diseases,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 302, no. 11, pp. H2148–H2165, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Monteiro and I. Azevedo, “Chronic inflammation in obesity and the metabolic syndrome,” Mediators of Inflammation, vol. 2010, Article ID 289645, 10 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Calabro, D. W. Chang, J. T. Willerson, and E. T. H. Yeh, “Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation,” Journal of the American College of Cardiology, vol. 46, no. 6, pp. 1112–1113, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. M. E. Trujillo and P. E. Scherer, “Adipose tissue-derived factors: impact on health and disease,” Endocrine Reviews, vol. 27, no. 7, pp. 762–778, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. S. J. Semple, “C-reactive protein-biological functions, cardiovascular disease and physical exercise,” South African Journal of Sports Medicine, vol. 18, no. 1, pp. 24–28, 2006. View at Google Scholar
  30. M. Agassandian, G. V. Shurin, Y. Ma, and M. R. Shurin, “C-reactive protein and lung diseases,” The International Journal of Biochemistry & Cell Biology, vol. 53, pp. 77–88, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. J. M. Gould and J. N. Weiser, “Expression of C-reactive protein in the human respiratory tract,” Infection and Immunity, vol. 69, no. 3, pp. 1747–1754, 2001. View at Publisher · View at Google Scholar · View at Scopus
  32. W. J. Jabs, B. A. Lögering, P. Gerke et al., “The kidney as a second site of human C-reactive protein formation in vivo,” European Journal of Immunology, vol. 33, no. 1, pp. 152–161, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Devaraj, N. Torok, M. R. Dasu, D. Samols, and I. Jialal, “Adiponectin decreases C-reactive protein synthesis and secretion from endothelial cells: evidence for an adipose tissue-vascular loop,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 7, pp. 1368–1374, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. P. Calabro, J. T. Willerson, and E. T. H. Yeh, “Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells,” Circulation, vol. 108, no. 16, pp. 1930–1932, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Kobayashi, N. Inoue, Y. Ohashi et al., “Interaction of oxidative stress and inflammatory response in coronary plaque instability: important role of C-reactive protein,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 8, pp. 1398–1404, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. G. Huang, C. Luo, X. Gu et al., “Mechanical strain induces expression of C-reactive protein in human blood vessels,” Journal of Pharmacology and Experimental Therapeutics, vol. 330, no. 1, pp. 206–211, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. J. G. Filep, “Platelets affect the structure and function of C-reactive protein,” Circulation Research, vol. 105, no. 2, pp. 109–111, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Boncler and C. Watała, “Regulation of cell function by isoforms of C-reactive protein: a comparative analysis,” Acta Biochimica Polonica, vol. 56, no. 1, pp. 17–31, 2009. View at Google Scholar · View at Scopus
  39. M. Kaplan, S. Hamoud, Y. Tendler et al., “A significant correlation between C-reactive protein levels in blood monocytes derived macrophages versus content in carotid atherosclerotic lesions,” Journal of Inflammation, vol. 11, no. 1, article 7, 2014. View at Publisher · View at Google Scholar
  40. S. U. Eisenhardt, J. R. Thiele, H. Bannasch, G. B. Stark, and K. Peter, “C-reactive protein: how conformational changes influence inflammatory properties,” Cell Cycle, vol. 8, no. 23, pp. 3885–3892, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. I. Ciubotaru, L. A. Potempa, and R. C. Wander, “Production of modified C-reactive protein in Uf937-derived macrophages,” Experimental Biology and Medicine, vol. 230, no. 10, pp. 762–770, 2005. View at Google Scholar · View at Scopus
  42. M. Miguel-Turu, J. Martínez, A. Luque et al., “Expresión de la proteína C reactiva en placas ateroscleróticas de carótida,” Clinica e Investigación en Arteriosclerosis, vol. 20, no. 3, pp. 95–101, 2008. View at Google Scholar
  43. S. J. Kim, D. Gershov, X. Ma, N. Brot, and K. B. Elkon, “I-PLA2 activation during apoptosis promotes the exposure of membrane lysophosphatidylcholine leading to binding by natural immunoglobulin M antibodies and complement activation,” Journal of Experimental Medicine, vol. 196, no. 5, pp. 655–665, 2002. View at Publisher · View at Google Scholar · View at Scopus
  44. S. U. Eisenhardt, J. Habersberger, A. Murphy et al., “Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques,” Circulation Research, vol. 105, no. 2, pp. 128–137, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. S.-R. Ji, Y. Wu, L. Zhu et al., “Cell membranes and liposomes dissociate C-reactive protein (CRP) to form a new, biologically active structural intermediate: mCRPm,” The FASEB Journal, vol. 21, no. 1, pp. 284–294, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. J. E. Volanakis and K. W. A. Wirtz, “Interaction of C-reactive protein with artificial phosphatidylcholine bilayers,” Nature, vol. 281, no. 5727, pp. 155–157, 1979. View at Publisher · View at Google Scholar · View at Scopus
  47. E. Paffen and M. P. M. deMaat, “C-reactive protein in atherosclerosis: a causal factor?” Cardiovascular Research, vol. 71, no. 1, pp. 30–39, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. E. E. Diehl, G. K. Haines III, J. A. Radosevich, and L. A. Potempa, “Immunohistochemical localization of modified C-reactive protein antigen in normal vascular tissue,” The American Journal of the Medical Sciences, vol. 319, no. 2, pp. 79–83, 2000. View at Publisher · View at Google Scholar · View at Scopus
  49. M. S. Wang, J. C. Black, M. K. Knowles, and S. M. Reed, “C-reactive protein (CRP) aptamer binds to monomeric but not pentameric form of CRP,” Analytical and Bioanalytical Chemistry, vol. 401, no. 4, pp. 1309–1318, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. N. Orito, S. Umekage, K. Sato et al., “High-affinity RNA aptamers to C-reactive protein (CRP): newly developed pre-elution methods for aptamer selection,” Journal of Physics: Conference Series, vol. 352, no. 1, Article ID 012042, pp. 12042–12054, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Agrawal, D. J. Hammond Jr., and S. K. Singh, “Atherosclerosis-related functions of C-reactive protein,” Cardiovascular and Hematological Disorders—Drug Targets, vol. 10, no. 4, pp. 235–240, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. M.-K. Chang, C. J. Binder, M. Torzewski, and J. L. Witztum, “C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 20, pp. 13043–13048, 2002. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Agrawal, A. K. Shrive, T. J. Greenhough, and J. E. Volanakis, “Topology and structure of the C1q-binding site on C-reactive protein,” The Journal of Immunology, vol. 166, no. 6, pp. 3998–4004, 2001. View at Publisher · View at Google Scholar · View at Scopus
  54. D. J. Hammond Jr., S. K. Singh, J. A. Thompson et al., “Identification of acidic pH-dependent ligands of pentameric C-reactive protein,” Journal of Biological Chemistry, vol. 285, no. 46, pp. 36235–36244, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. A. J. Szalai, “An about-face for C-reactive protein?” Clinical Chemistry, vol. 57, no. 10, pp. 1351–1352, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Mihlan, M. Hebecker, H.-M. Dahse et al., “Human complement factor H-related protein 4 binds and recruits native pentameric C-reactive protein to necrotic cells,” Molecular Immunology, vol. 46, no. 3, pp. 335–344, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. N. G. Frangogiannis, “Monomeric C-reactive protein and inflammatory injury in myocardial infarction,” Cardiovascular Research, vol. 96, no. 1, pp. 4–6, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. L. M. Amezcua, S. Springall, and R. Bojalil, “Proteína C reactiva: aspectos cardiovasculares de una proteína de fa se aguda,” Archivos de cardiología de México, vol. 77, no. 1, pp. 58–66, 2007. View at Google Scholar
  59. M. L. Baltz, F. C. de Beer, A. Feinstein et al., “Phylogenetic aspects of C-reactive protein and related proteins,” Annals of the New York Academy of Sciences, vol. 389, pp. 49–75, 1982. View at Publisher · View at Google Scholar · View at Scopus
  60. M. Boncler, J. Rywaniak, J. Szymański, L. A. Potempa, B. Rychlik, and C. Watała, “Modified C-reactive protein interacts with platelet glycoprotein Ibα,” Pharmacological Reports, vol. 63, no. 2, pp. 464–475, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. L. Li, N. Roumeliotis, T. Sawamura, and G. Renier, “C-reactive protein enhances LOX-1 expression in human aortic endothelial cells: relevance of LOX-1 to C-reactive protein-induced endothelial dysfunction,” Circulation Research, vol. 95, no. 9, pp. 877–883, 2004. View at Publisher · View at Google Scholar · View at Scopus
  62. H. H. Shih, S. Zhang, W. Cao et al., “CRP is a novel ligand for the oxidized LDL receptor LOX-1,” American Journal of Physiology: Heart and Circulatory Physiology, vol. 296, no. 5, pp. H1643–H1650, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. Y. Fujita, S. Yamaguchi, A. Kakino, S. Iwamoto, R. Yoshimoto, and T. Sawamura, “Lectin-like oxidized LDL receptor 1 is involved in CRP-mediated complement activation,” Clinical Chemistry, vol. 57, no. 10, pp. 1398–1405, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. T. W. Hein, E. Qamirani, Y. Ren, X. Xu, N. Thengchaisri, and L. Kuo, “Selective activation of lectin-like oxidized low-density lipoprotein receptor-1 mediates C-reactive protein-evoked endothelial vasodilator dysfunction in coronary arterioles,” Circulation Research, vol. 114, no. 1, pp. 92–100, 2014. View at Publisher · View at Google Scholar · View at Scopus
  65. A. J. Szalai, “An about-face for C-reactive protein?” Clinical Chemistry, vol. 57, no. 10, pp. 1351–1353, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. X. Q. Zhao, M. W. Zhang, F. Wang et al., “CRP enhances soluble LOX-1 release from macrophages by activating TNF-α converting enzyme,” Journal of Lipid Research, vol. 52, no. 5, pp. 923–933, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. R. Takanabe-Mori, K. Ono, H. Wada et al., “Lectin-like oxidized low-density lipoprotein receptor-1 plays an important role in vascular inflammation in current smokers,” Journal of Atherosclerosis and Thrombosis, vol. 20, no. 6, pp. 585–590, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. F. Kamezaki, K. Yamashita, H. Tasaki et al., “Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 correlates with oxidative stress markers in stable coronary artery disease,” International Journal of Cardiology, vol. 134, no. 2, pp. 285–287, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. N. Kume, H. Mitsuoka, K. Hayashida, M. Tanaka, and T. Kita, “Soluble lectin-like oxidized low-density lipoprotein receptor-1 predicts prognosis after acute coronary syndrome: a pilot study,” Circulation Journal, vol. 74, no. 7, pp. 1399–1404, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. C.-S. Chu, Y.-C. Wang, L.-S. Lu et al., “Electronegative low-density lipoprotein increases C-reactive protein expression in vascular endothelial cells through the LOX-1 receptor,” PLoS ONE, vol. 8, no. 8, Article ID e70533, 2013. View at Publisher · View at Google Scholar · View at Scopus
  71. F. Nimmerjahn and J. Ravetch, “Fcg receptors: old friends and new family members,” Immunity, vol. 24, no. 1, pp. 19–28, 2006. View at Google Scholar
  72. C. Zhang, “Linking inflammation and thrombosis: role of C-reactive protein,” World Journal of Cardiology, vol. 2, no. 11, pp. 365–369, 2010. View at Google Scholar
  73. A. Bíró, Z. Rovó, D. Papp et al., “Studies on the interactions between C-reactive protein and complement proteins,” Immunology, vol. 121, no. 1, pp. 40–50, 2007. View at Publisher · View at Google Scholar · View at Scopus
  74. R. R. S. Packard and P. Libby, “Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction,” Clinical Chemistry, vol. 54, no. 1, pp. 24–38, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. C. Cheong and J.-H. Choi, “Dendritic cells and regulatory T cells in atherosclerosis,” Molecules and Cells, vol. 34, no. 4, pp. 341–347, 2012. View at Publisher · View at Google Scholar · View at Scopus
  76. F. D. McGrath, M. C. Brouwer, G. J. Arlaud, M. R. Daha, C. E. Hack, and A. Roos, “Evidence that complement protein C1q interacts with C-reactive protein through its globular head region,” The Journal of Immunology, vol. 176, no. 5, pp. 2950–2957, 2006. View at Publisher · View at Google Scholar · View at Scopus
  77. M. Mihlan, S. Stippa, M. Józsi, and P. F. Zipfel, “Monomeric CRP contributes to complement control in fluid phase and on cellular surfaces and increases phagocytosis by recruiting factor H,” Cell Death and Differentiation, vol. 16, no. 12, pp. 1630–1640, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. A. I. Okemefuna, R. Nan, A. Miller, J. Gor, and S. J. Perkins, “Complement factor H binds at two independent sites to C-reactive protein in acute phase concentrations,” The Journal of Biological Chemistry, vol. 285, no. 2, pp. 1053–1065, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. K. Yasojima, C. Schwab, E. G. McGeer, and P. L. McGeer, “Generation of C-reactive protein and complement components in atherosclerotic plaques,” The American Journal of Pathology, vol. 158, no. 3, pp. 1039–1051, 2001. View at Publisher · View at Google Scholar · View at Scopus
  80. R. D. Lewis, C. L. Jackson, B. P. Morgan, and T. R. Hughes, “The membrane attack complex of complement drives the progression of atherosclerosis in apolipoprotein E knockout mice,” Molecular Immunology, vol. 47, no. 5, pp. 1098–1105, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. M. B. Pepys and G. M. Hirschfield, “C-reactive protein: a critical update,” Journal of Clinical Investigation, vol. 111, no. 12, pp. 1805–1812, 2003. View at Publisher · View at Google Scholar · View at Scopus
  82. P. Théroux and C. Martel, “Complement activity and pharmacological inhibition in cardiovascular disease,” Canadian Journal of Cardiology, vol. 22, pp. 18B–24B, 2006. View at Google Scholar · View at Scopus
  83. E. Shagdarsuren, K. Bidzhekov, S. F. Mause et al., “C5a receptor targeting in neointima formation after arterial injury in atherosclerosis-prone mice,” Circulation, vol. 122, no. 10, pp. 1026–1036, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. S. P. Kastl, W. S. Speidl, C. Kaun et al., “The complement component C5a induces the expression of plasminogen activator inhibitor-1 in human macrophages via NF-κB activation,” Journal of Thrombosis and Haemostasis, vol. 4, no. 8, pp. 1790–1797, 2006. View at Publisher · View at Google Scholar · View at Scopus
  85. L. Gómez, C. Cañas, and J. M. Anaya, “Receptores Fc g y autoinmunidad,” Acta Médica Colombiana, vol. 30, pp. 27–35, 2005. View at Google Scholar
  86. X. Li, T. S. Ptacek, E. E. Brown, and J. C. Edberg, “Fcγ receptors: structure, function and role as genetic risk factors in SLE,” Genes and Immunity, vol. 10, no. 5, pp. 380–389, 2009. View at Publisher · View at Google Scholar · View at Scopus
  87. D. Kawanami, K. Maemura, N. Takeda et al., “C-reactive protein induces VCAM-1 gene expression through NF-κB activation in vascular endothelial cells,” Atherosclerosis, vol. 185, no. 1, pp. 39–46, 2006. View at Publisher · View at Google Scholar · View at Scopus
  88. Y. Hattori, M. Matsumura, and K. Kasai, “Vascular smooth muscle cell activation by C-reactive protein,” Cardiovascular Research, vol. 58, no. 1, pp. 186–195, 2003. View at Publisher · View at Google Scholar · View at Scopus
  89. M. Chi, S. Tridandapani, W. Zhong, K. M. Coggeshall, and R. F. Mortensen, “C-reactive protein induces signaling through FcγRIIa on HL-60 granulocytes,” Journal of Immunology, vol. 168, no. 3, pp. 1413–1418, 2002. View at Publisher · View at Google Scholar · View at Scopus
  90. S. Devaraj and I. Jialal, “C-reactive protein polarizes human macrophages to an M1 phenotype and inhibits transformation to the M2 phenotype,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 6, pp. 1397–1402, 2011. View at Publisher · View at Google Scholar · View at Scopus
  91. K. S. Venugopal, S. Devaraj, and I. Jialal, “C-reactive protein decreases prostacyclin release from human aortic endothelial cells,” Circulation, vol. 108, no. 14, pp. 1676–1678, 2003. View at Publisher · View at Google Scholar · View at Scopus
  92. G. Nickenig and D. G. Harrison, “The AT1-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis,” Circulation, vol. 105, no. 3, pp. 393–396, 2002. View at Publisher · View at Google Scholar · View at Scopus
  93. I. Ahrens, H. Domeij, S. U. Eisenhardt et al., “Opposing effects of monomeric and pentameric C-reactive protein on endothelial progenitor cells,” Basic Research in Cardiology, vol. 106, no. 5, pp. 879–895, 2011. View at Publisher · View at Google Scholar · View at Scopus
  94. S. U. Eisenhardt, J. Habersberger, and K. Peter, “Monomeric C-reactive protein generation on activated platelets: the missing link between inflammation and atherothrombotic risk,” Trends in Cardiovascular Medicine, vol. 19, no. 7, pp. 232–237, 2009. View at Publisher · View at Google Scholar · View at Scopus
  95. B. Molins, E. Peña, G. Vilahur, C. Mendieta, M. Slevin, and L. Badimon, “C-reactive protein isoforms differ in their effects on thrombus growth,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 12, pp. 2239–2246, 2008. View at Publisher · View at Google Scholar · View at Scopus
  96. U. Singh, M. R. Dasu, P. G. Yancey, A. Afify, S. Devaraj, and I. Jialal, “Human C-reactive protein promotes oxidized low density lipoprotein uptake and matrix metalloproteinase-9 release in wistar rats,” Journal of Lipid Research, vol. 49, no. 5, pp. 1015–1023, 2008. View at Publisher · View at Google Scholar · View at Scopus
  97. G. Cimmino, M. Ragni, P. Cirillo et al., “C-reactive protein induces expression of matrix metalloproteinase-9: a possible link between inflammation and plaque rupture,” International Journal of Cardiology, vol. 168, no. 2, pp. 981–986, 2013. View at Publisher · View at Google Scholar · View at Scopus
  98. G. Doronzo, I. Russo, L. Mattiello, M. Trovati, and G. Anfossi, “C-reactive protein increases matrix metalloproteinase-2 expression and activity in cultured human vascular smooth muscle cells,” The Journal of Laboratory and Clinical Medicine, vol. 146, no. 5, pp. 287–298, 2005. View at Publisher · View at Google Scholar · View at Scopus
  99. W. K. Alderton, C. E. Cooper, and R. G. Knowles, “Nitric oxide synthases: structure, function and inhibition,” Biochemical Journal, vol. 357, no. 3, pp. 593–615, 2001. View at Publisher · View at Google Scholar · View at Scopus
  100. I. Jialal, S. Verma, and S. Devaraj, “Inhibition of endothelial nitric oxide synthase by C-reactive protein: clinical relevance,” Clinical Chemistry, vol. 55, no. 2, pp. 206–208, 2009. View at Publisher · View at Google Scholar · View at Scopus
  101. S. Devaraj, D. Siegel, and I. Jialal, “Statin therapy in metabolic syndrome and hypertension post-JUPITER: what is the value of CRP?” Current Atherosclerosis Reports, vol. 13, no. 1, pp. 31–42, 2011. View at Publisher · View at Google Scholar · View at Scopus
  102. U. Singh, S. Devaraj, J. Vasquez-Vivar, and I. Jialal, “C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling,” Journal of Molecular and Cellular Cardiology, vol. 43, no. 6, pp. 780–791, 2007. View at Publisher · View at Google Scholar · View at Scopus
  103. C. Mineo, A. K. Gormley, I. S. Yuhanna et al., “FcγRIIB mediates C-reactive protein inhibition of endothelial NO synthase,” Circulation Research, vol. 97, no. 11, pp. 1124–1131, 2005. View at Publisher · View at Google Scholar · View at Scopus
  104. K. Tanigaki, C. Mineo, I. S. Yuhanna et al., “C-reactive protein inhibits insulin activation of endothelial nitric oxide synthase via the immunoreceptor tyrosine-based inhibition motif of FcγRIIB and SHIP-1,” Circulation Research, vol. 104, no. 11, pp. 1275–1282, 2009. View at Publisher · View at Google Scholar · View at Scopus
  105. S. Valleggi, S. Devaraj, M. R. Dasu, and I. Jialal, “C-reactive protein adversely alters the protein-protein interaction of the endothelial isoform of nitric oxide synthase,” Clinical Chemistry, vol. 56, no. 8, pp. 1345–1348, 2010. View at Publisher · View at Google Scholar · View at Scopus
  106. S. B. Schwedler, T. Hansen-Hagge, M. Reichert et al., “Monomeric C-reactive protein decreases acetylated LDL uptake in human endothelial cells,” Clinical Chemistry, vol. 55, no. 9, pp. 1728–1731, 2009. View at Publisher · View at Google Scholar · View at Scopus
  107. W. Song, H. Wang, Y. Wang, L. Chen, Q. Fang, and X. Yan, “C-reactive protein upregulates lectin-like oxidized LDL receptor-1 expression in THP-1-derived macrophages through NF-κB,” European Journal of Lipid Science and Technology, vol. 113, no. 5, pp. 584–591, 2011. View at Publisher · View at Google Scholar · View at Scopus
  108. S. Devaraj, U. Singh, and I. Jialal, “The evolving role of C-reactive protein in atherothrombosis,” Clinical Chemistry, vol. 55, no. 2, pp. 229–238, 2009. View at Publisher · View at Google Scholar · View at Scopus
  109. S. K. Singh, D. J. Hammond Jr., B. W. Beeler, and A. Agrawal, “The binding of C-reactive protein, in the presence of phosphoethanolamine, to low-density lipoproteins is due to phosphoethanolamine-generated acidic pH,” Clinica Chimica Acta, vol. 409, no. 1-2, pp. 143–144, 2009. View at Publisher · View at Google Scholar · View at Scopus
  110. S. K. Singh, A. Thirumalai, D. J. Hammond Jr. et al., “Exposing a hidden functional site of C-reactive protein by site-directed mutagenesis,” The Journal of Biological Chemistry, vol. 287, no. 5, pp. 3550–3558, 2012. View at Publisher · View at Google Scholar · View at Scopus
  111. M. B. Pepys, I. F. Rowe, and M. L. Baltz, “C-Reactive protein: binding to lipids and lipoproteins,” International Review of Experimental Pathology, vol. 27, pp. 83–111, 1985. View at Google Scholar · View at Scopus
  112. F. C. de Beer, A. K. Soutar, M. L. Baltz, I. M. Trayner, A. Feinstein, and M. B. Pepys, “Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein,” Journal of Experimental Medicine, vol. 156, no. 1, pp. 230–242, 1982. View at Publisher · View at Google Scholar · View at Scopus
  113. S. Bhakdi, M. Torzewski, M. Klouche, and M. Hemmes, “Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 10, pp. 2348–2354, 1999. View at Publisher · View at Google Scholar · View at Scopus
  114. S. U. Eisenhardt, J. Starke, J. R. Thiele et al., “Pentameric CRP attenuates inflammatory effects of mmLDL by inhibiting mmLDL-monocyte interactions,” Atherosclerosis, vol. 224, no. 2, pp. 384–393, 2012. View at Publisher · View at Google Scholar · View at Scopus
  115. A. Agrawal, T. B. Gang, and A. E. Rusiñol, “Recognition functions of pentameric C-reactive protein in cardiovascular disease,” Mediators of Inflammation, vol. 2014, Article ID 319215, 6 pages, 2014. View at Publisher · View at Google Scholar
  116. B. Molins, E. Peña, R. de La Torre, and L. Badimon, “Monomeric C-reactive protein is prothrombotic and dissociates from circulating pentameric C-reactive protein on adhered activated platelets under flow,” Cardiovascular Research, vol. 92, no. 2, pp. 328–337, 2011. View at Publisher · View at Google Scholar · View at Scopus
  117. R. Li, M. Ren, M. Luo et al., “Monomeric C-reactive protein alters fibrin clot properties on endothelial cells,” Thrombosis Research, vol. 129, no. 5, pp. e251–e256, 2012. View at Publisher · View at Google Scholar · View at Scopus
  118. M. Fujita, Y. K. Takada, and Y. Izumiya, “The binding of monomeric C-reactive protein (mCRP) to integrins αvβ3 and α4β1 is related to its pro-inflammatory action,” PLoS ONE, vol. 9, no. 4, Article ID e93738, 2014. View at Publisher · View at Google Scholar · View at Scopus
  119. J. Salazar, M. S. Martínez, M. Chávez et al., “C-reactive protein: clinical and epidemiological perspectives,” Cardiology Research and Practice, vol. 2014, Article ID 605810, 10 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  120. C. R. Kiefer, R. E. Stock, S. S. Flanagan, C. E. Darling, C. S. Smith, and L. M. Snyder, “Early verification of myocardial ischemia with a novel biomarker of acute tissue damage: C-reactive protein fractional forms,” Clinica Chimica Acta, vol. 413, no. 19-20, pp. 1536–1541, 2012. View at Publisher · View at Google Scholar · View at Scopus
  121. J. Oh, H. Teoh, and L. A. Leiter, “Should C-reactive protein be a target of therapy?” Diabetes Care, vol. 34, no. 2, pp. S155–S160, 2011. View at Publisher · View at Google Scholar · View at Scopus
  122. R. Kones, “Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease -a perspective,” Drug Design, Development and Therapy, vol. 4, pp. 383–413, 2010. View at Publisher · View at Google Scholar · View at Scopus